Whyand Tara, Bouvier Catherine, Davies Philippa
Neuroendocrine tumour (NET) Research and Development Dietitian, Royal Free Hospital, London.
Chief Executive, NET Patient Foundation, Leamington Spa, London.
Br J Nurs. 2018 Jul 12;27(13):738-744. doi: 10.12968/bjon.2018.27.13.738.
Somatostatin analogues (SSA) are a common treatment for some forms of neuroendocrine tumours (NETs). Patients report a variety of side effects after starting these drugs, so in most cases they require a lot of nutritional input. The authors used an online survey to invite responses from patients worldwide to determine the extent of reported side effects. Patients were asked which SSA they were taking and how they rated the severity of their side effects. They were provided with a list of 11 options to choose from, but not given any guidance or a definition of terms. The most commonly reported side effect was constipation (85%), with 8.6% of these respondents rating its severity as 10/10. The survey found that many self-reported side effects from the use of SSAs were experienced more frequently than previous clinical studies or the patient information leaflets reported. As this was an online survey, so the findings are limited in that first, this was a self-selected sample of patients and second, patients were able to respond more than once.
生长抑素类似物（SSA）是治疗某些类型神经内分泌肿瘤（NETs）的常用药物。患者在开始使用这些药物后会出现各种副作用，因此在大多数情况下，他们需要大量的营养支持。作者通过在线调查邀请全球患者参与，以确定所报告副作用的程度。患者被问及正在服用哪种SSA以及如何对副作用的严重程度进行评分。他们被提供了一份包含11个选项的列表以供选择，但没有得到任何指导或术语定义。最常报告的副作用是便秘（85%），其中8.6%的受访者将其严重程度评为10/10。调查发现，许多患者自我报告的使用SSA后的副作用比以往临床研究或患者信息手册所报告的更为频繁。由于这是一项在线调查，因此研究结果存在局限性，首先，这是一个患者自行选择的样本，其次，患者能够多次回复。
